Defunct Company
Total Trials
10
As Lead Sponsor
As Collaborator
0
Total Enrollment
519
NCT04082936
A Study of Imvotamab Monotherapy and in Combination in Subjects With Relapsed/Refractory Non-Hodgkin Lymphoma
Phase: Phase 1/2
Role: Lead Sponsor
Start: Sep 30, 2019
Completion: Feb 22, 2024
NCT04553692
Phase 1a/1b Study of Aplitabart (IGM-8444) Alone or in Combination in Participants with Relapsed, Refractory, or Newly Diagnosed Cancers
Phase: Phase 1
Start: Sep 23, 2020
Completion: Jan 20, 2025
NCT05160402
Evaluation of IGM-6268 in Healthy Volunteers
Start: Dec 7, 2021
Completion: Aug 18, 2022
NCT05184218
Evaluation of IGM-6268 in Healthy Adults and Patients With Mild to Moderate COVID-19
Start: Jan 20, 2022
Completion: Jul 4, 2022
NCT05702424
Evaluation of IGM-7354 in Adults With Relapsed and/or Refractory Cancer
Start: Jan 10, 2023
Completion: May 31, 2024
NCT06087406
A Phase 1b Study of Imvotamab in Moderate to Severe Rheumatoid Arthritis
Start: Mar 15, 2023
Completion: Feb 10, 2025
NCT06041568
A Study of Imvotamab in Severe Systemic Lupus Erythematosus
Start: Aug 15, 2023
Completion: Jan 27, 2025
NCT05908396
Evaluation of IGM-2644 in Adults With Relapsed and/or Refractory Multiple Myeloma
Start: Aug 29, 2023
Completion: Feb 16, 2024
NCT06524687
A Study of Imvotamab in Active, Refractory Idiopathic Inflammatory Myopathies
Start: May 29, 2024
Completion: Jan 21, 2025